Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Das führende russische Pharmaunternehmen BIOCAD hat heute eine Marktzulassung für das Bevacizumab-Biosimilar erhalten. Das russische...
L'entreprise biopharmaceutique russe de premier plan, BIOCAD a obtenu aujourd'hui une autorisation de mise sur le marché du biosimilaire bévacizumab. ...
A leading Russian biopharmaceutical company BIOCAD obtained a Marketing Authorization for the bevacizumab biosimilar today. The Russian MoH has...
Biopharmaceutical company BIOCAD is now the world leader in sales of biosimilar rituximab. Company revenue from sales of Acellbia™, exceeded $155...
Russian pharmaceutical companies are actively squeezing out foreign therapeutic manufacturers from the government tenders. The рatients' support...
On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company ...
Head of the Russian Government Dmitri Medvedev visited today CJSC BIOCAD's commercial manufacturing facility for mAb-based therapeutic proteins. This ...
The rituximab biosimilar, to be marketed under the trade name AcellBia™, is the first mAb biosimilar which received the affirmative decision on...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.